After hours: February 4 at 4:20:01 PM EST Loading Chart for MIRM ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Figure 1. The main pathways leading to mitochondrial-associated neurological disorders. Genetic or environmental factors can cause mutations of mitochondrial proteins, which lead to mitochondrial ...

The molecular mechanism underlying fugu5-mediated compensation is in good agreement with the cell-autonomous nature of cellular metabolic disorders. Because phytohormones usually reflect the ...

28, 2025 — Schizophrenia is a serious mental disorder that affects around 1% of the world's population. Researchers have identified a deficit in contrast perception in people with schizophrenia.

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...